ClinicalTrials.gg
RecruitingNCT06889818JOY-ALZUpdated Mar 21, 2025

Korean Joint Registry for Alzheimer's Treatment and Diagnostics (JOY-ALZ)

An observational study in Mild Cognitive Impairment, Dementia and Subjective Cognitive Decline (SCD), sponsored by Ewha Womans University Mokdong Hospital. Recruiting at 3 sites in Korea, Republic of. Open to participants aged 19 Years and older, including healthy volunteers. Per ClinicalTrials.gov, last updated 2025-03-21.

Sponsored by Ewha Womans University Mokdong Hospital · Observational

How we know

From the registry’s dates

  • Started Feb 2025; still recruiting 1 year 8 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Study type
Observational
Model
Case-only
Time perspective
Prospective
Enrollment
4,000
Ages
19 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 74 studies in Cognitive Dysfunction with a site in Korea, Republic of — 17 open to participants now, 24 under way, 5 of them phase 3. Cognitive Dysfunction · Korea, Republic of.

Planned enrollment
Largest of 17
4,000 · median 163
Started
2025
with 12 others
Observational
17 of 74
4 open now
Primary completion
2034-12
later than 22 of 23 live
Registered
60th of 74
by date

Among the 74 studies in Cognitive Dysfunction with a site in Korea, Republic of, this one has the largest planned enrollment of the 17 observational ones that give a count, is one of 13 that started in 2025, is one of 17 observational ones, reaches primary completion later than 22 of the 23 other live ones, and was the 60th registered.

Cognitive Dysfunction

3,885 studies on the registry are indexed under Cognitive Dysfunction; 1,123 are open to participants now.

Browse Cognitive Dysfunction studies →

Open to participants now

17 of the 74 studies in Cognitive Dysfunction with a site in Korea, Republic of are open now. Recruiting first, the newest first:

11 more — sign in →

All 17 open studies →

A study can be open while its sites in Korea, Republic of have not opened yet or have stopped. Only those recruiting at a site in Korea, Republic of →

Who these studies take

Of the 751 Cognitive Dysfunction studies recruiting now, 361 (48%) set no upper age limit and 144 (19%) stop at 75 or younger; 46 take children under 18; 260 take healthy volunteers.

This study: 19 Years and older · all sexes · healthy volunteers too.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 74 studies in Cognitive Dysfunction with a site in Korea, Republic of, or all of them as a file.
02

Study summary

The purpose of this research is to investigate the long-term effectiveness and safety of new Alzheimer's disease treatments, particularly monoclonal antibody therapies like lecanemab and donanemab, as well as to enhance diagnostic methods for Alzheimer's disease by collecting real-world data from Korean Alzheimer's patients. The goal is to contribute to the precision of Alzheimer's treatment and to evaluate the impact of these new therapies and diagnostic techniques in clinical practice.

Read the detailed description

In 2024, it is estimated that there will be over 1 million individuals aged 65 and older with dementia in South Korea, with national dementia care costs exceeding approximately 17 trillion KRW (0.9% of GDP). South Korea is experiencing rapid population aging, leading to a projected significant increase in both the number of patients and the associated socio-economic costs. Alzheimer's disease (AD) is the most common cause of dementia and cognitive impairment in the elderly, characterized by the abnormal accumulation of amyloid beta (Aβ) and tau proteins in the brain. Research has shown that beta-amyloid protein begins to accumulate in the brain over 20 years before the onset of memory impairment symptoms. Consequently, Alzheimer's disease progresses through a prolonged asymptomatic stage of normal cognitive function (cognitively unimpaired, CU) to subjective cognitive decline, mild cognitive impairment, and dementia.

In May 2024, the Korean Ministry of Food and Drug Safety approved lecanemab for the treatment of Alzheimer's disease. Recent advancements have been made in the development of new treatments and diagnostic methods for Alzheimer's disease, with some already approved for use in South Korea or anticipated to receive approval soon. These developments are expected to significantly impact the management of dementia and cognitive impairment patients in the near future. Among the new treatments, monoclonal antibody injections targeting the core pathological mechanism of Alzheimer's disease, which is the removal of beta-amyloid protein (e.g., lecanemab, donanemab), currently lack long-term efficacy data, providing only 1-2 years of investigatory data in clinical trials. Such medications may have side effects, including amyloid-related imaging abnormalities (ARIA) such as brain edema or microbleeding and infusion-related adverse reactions. For the advancement of precise treatments for Alzheimer's disease, it is essential to monitor long-term effects and side effects of these drugs in clinical practice to collect and analyze more extensive clinical data to establish additional clinical evidence.

Moreover, the phase 3 clinical trial data for lecanemab suggests that the drug's effectiveness and side effects may vary by ethnicity. Recently, a diagnostic technique that measures Elecsys beta-amyloid 42 (Aβ42) and Elecsys Phospho-Tau181 (ptau181) in cerebrospinal fluid (CSF) has received approval from the Korean Ministry of Food and Drug Safety for the diagnosis of Alzheimer's disease. Additionally, there is a strong potential for new diagnostic methods that measure proteins such as ptau217, ptau181, and Aβ42 in blood to be commercialized in clinical practice. Future advancements through real-world data collection on these new diagnostic methods will be necessary.

The Alzheimer's Association (AA) and researchers in the United States have initiated a registry study named the Alzheimer's Network for Treatment and Diagnostics (ALZ-NET) to collect real-world data on new treatments and diagnostic methods for Alzheimer's disease. Longitudinal studies to investigate the long-term effectiveness and safety of new treatments and diagnostic methods in Alzheimer's patients are also being established in countries such as Japan, Australia, the Netherlands, and Europe. In response to these changes in Alzheimer's disease management, the researchers aim to contribute to the precision of Alzheimer's treatment and the enhancement of new diagnostic methods by collecting real-world data from Korean Alzheimer's patients regarding the long-term effectiveness and safety of new therapies.

03

Conditions studied

  • Mild Cognitive Impairment
  • Dementia
  • Subjective Cognitive Decline (SCD)
  • Alzheimer Disease

Keywords

  • Real World Data
  • Lecanemab
04

Who can participate

Ages eligible
19 Years and older
Sexes eligible
All
Accepts healthy volunteers
Yes
Sampling method
Probability sample

Study population

Approximately 40 medical institutions nationwide are expected to participate in the study over a period of 10 years, with about 4,000 participants in total. Our institution anticipates the participation of approximately 100 subjects. Participants in this study are adults with Alzheimer's disease dementia, mild cognitive impairment, or normal cognitive function (including subjective cognitive decline) who are undergoing medical evaluation for newly approved Alzheimer's disease medications after 2021, have made the decision to initiate treatment with these medications, or have already begun treatment with these newly approved Alzheimer's disease medications.

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Participants must be 19 years of age or older at the time of .
  2. Patients who are undergoing medical evaluation for newly approved Alzheimer's disease medications after 2021, patients who have decided to initiate treatment with these medications in consultation with their physician after 2021, or patients who have already started treatment with newly approved Alzheimer's disease medications after 2021.
  3. Patients who have undergone an amyloid PET scan to confirm Alzheimer's disease pathology, or cerebrospinal fluid testing for Aβ42 and ptau181.
  4. Clinical diagnosis of Alzheimer's disease, defined as follows:

<!-- -->

  1. [Alzheimer's Disease Dementia (ADD)] - Must meet the criteria for probable Alzheimer's dementia as defined by the National Institute on Aging and the Alzheimer's Association working groups (NIA-AA).

    • Must exhibit cognitive decline that impairs independent daily living.
  2. [Mild Cognitive Impairment (MCI)]

    • Must meet NIA-AA diagnostic criteria for MCI.
    • The subject or informant must report cognitive decline.
    • Performance on delayed recall of verbal memory must be more than -1.0 SD below the age- and education-adjusted normative mean, or scores on any one or more tests of executive function, language, visuospatial abilities, or attention must be more than -1.5 SD below the age- and education-adjusted normative mean.
    • Clinical Dementia Rating scale (CDR) of 0.5.
    • Maintenance of independent daily living ability.
    • Not categorized as dementia.
  3. [Cognitively Unimpaired (CU)]

    • Delayed recall of verbal memory must be at or above -1.0 SD versus the age- and education-adjusted normative mean, and all executive function, language, visuospatial abilities, and attention tests must be at or above -1.5 SD versus the age- and education-adjusted normative mean.
    • Maintenance of independent daily living ability.
    • If the subject reports cognitive decline, they will be classified as having Subjective Cognitive Decline (SCD).

      1. Patients must be ambulatory (use of mobility aids is acceptable). 6. The subject must provide written informed consent to participate in the study. In the case of dementia patients, additional written consent from a guardian is required.

Exclusion criteria

Exclusion Criteria:

  1. Presence of significant psychiatric disorders associated with intellectual disability, schizophrenia, major depression, bipolar disorder, delirium, etc.
  2. History of substance abuse or alcohol dependence that required treatment within the past five years.
  3. A current diagnosis of cancer that has not achieved remission within the past five years. However, localized prostate cancer, cervical carcinoma in situ, non-melanoma skin basal cell carcinoma, or squamous cell carcinoma are excluded.
  4. Evidence of severe or unstable physical conditions (e.g., dialysis, severe liver disease).
  5. Visual or auditory impairments that prevent the satisfactory assessment of cognitive function.
  6. Inability to perform MRI due to the presence of metallic substances in the body.
  7. Currently participating in another drug clinical trial.
  8. Currently pregnant or breastfeeding.
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

05

Study design

Observational model
Case-only
Time perspective
Prospective
Enrollment
4,000 participants (estimated)
Target follow-up
10 Years
Patient registry
Yes
Biospecimen retention
Samples with dna

Groups and cohorts

  • Open Label Registry

    Collection of real-world data from enrolled patients being evaluated for or receiving novel Korea MFDS-approved Alzheimer's disease treatments and diagnostics

06

What researchers measure

Primary outcomes

  1. Change from baseline in the Korean Mini-Mental State Examination-2 (K-MMSE-2) total score

    This test consists of orientation to time and place, three-word recall, subtracting 7 from 100 in succession, overlapping pentagon drawing, command execution, reading, writing, repeating, and naming. The score ranges from 0 to 30.

    Time frame: Up to 10 years

  2. Change from baseline in the Korean version of Montreal Cognitive Assessment (K-MOCA) total score

    This assessment evaluates memory, language, executive function, visuospatial construction, reasoning, and attention, with a scoring range of 0-30 points where higher scores indicate better cognitive function.

    Time frame: Up to 10 years

  3. Change from baseline in the Clinical Dementia Rating scale (CDR) total score

    Scores include a Global CDR (0-3 points) and a CDR-Sum of Boxes (SB) which sums the scores of the six domains (0-18 points). Higher scores indicate worse cognitive function.

    Time frame: Up to 10 years

  4. Change from baseline in the Functional Assessment Questionnaire (FAQ) total score

    The informant evaluates the subject, with a score range of 0-30, where higher scores indicate a decline in daily functioning. A score of 9 or more suggests significant deterioration in daily functioning.

    Time frame: Up to 10 years

  5. Change from baseline in the Korean version of the Alzheimer disease 8 (K-AD8) total score

    The score ranges from 0 to 8, where higher scores indicate more severe cognitive impairment.

    Time frame: Up to 10 years

Secondary outcomes

  1. Brain Magnetic Resonance Imaging (MRI)

    Data will be collected to diagnose cognitive impairment and to assess for emergence of amyloid related imaging abnormalities.

    Time frame: Up to 10 years

  2. Alzheimer's disease (AD) biomarkers

    Data from past amyloid Positron Emission Tomography (PET) scans will be collected for the diagnosis of AD. Results for cerebrospinal fluid assays of Elecsys Aβ42, Elecsys ptau181, and ptau181/Aβ42 will also be collected. A ptau181/Aβ42 ratio greater than 0.023 indicates a suggestion of AD.

    Time frame: Up to 10 years

07

Study locations

2 of 3 sites recruiting
08

References and documents

Individual participant data

Plan to share: Yes — Data will be shared with Eisai and gAAIN.

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Feb 2025 (actual). Primary completion is estimated for Dec 2034, 118 months after the start.

Of 506 non-industry observational studies under Cognitive Dysfunction, half reached primary completion within 49 months of starting (the median), counting those still running; a quarter within 22 and three quarters within 118. This study's planned 118 months is above that.

Counting every sponsor, half of 545 studies reached it within 48 months; a quarter within 21 and three quarters within 118.

How these figures are worked out, and which studies are left out of them.

Registered
Mar 14, 2025
First posted
Mar 21, 2025
StartActual
Feb 24, 2025
Primary completionEst.
Dec 31, 2034
CompletionEst.
Dec 31, 2034
Last update
Mar 21, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Mar 21, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT06889818
Lead sponsor
Ewha Womans University Mokdong Hospital
Collaborators
Korean Dementia Association, Inha University Hospital, Gachon University Gil Medical Center, Saint Vincent's Hospital, Korea, Gangnam Severance Hospital, Konkuk University Hospital, Kyunghee University Medical Center, Korea University Medicine, Busan University Medical Center, CHA University, Samsung Medical Center, Seoul National University Hospital, Seoul National University Bundang Hospital, Asan Medical Center, Soonchunhyang University Hospital, Ajou University Hospital, Suwon, South Korea, Yonsei University Yongin Severance Hospital, Wonkwang University Hospital, Ewha Womans University Seoul Hospital, InjeUniversityBusanPaikHospital, Chonnam National University Hospital, Jeju National University Hospital, Chungnam National University Hospital, Gyungbook national university hospital, Hanllym University Medical Center, Heavenly Clinical Research, KangWon National University Hospital, Seoul St. Mary's Hospital, The Catholic University
Responsible party
Geon Ha Kim (Principal Investigator, Ewha Womans University Mokdong Hospital) — Principal investigator
First posted
Mar 21, 2025
Start date
Feb 24, 2025
Primary completion
Dec 31, 2034 (estimated)
Completion
Dec 31, 2034 (estimated)
Last update
Mar 21, 2025

Study contacts

Geon-ha Kim
Contact
geonha@ewha.ac.kr
82-2-587-7462
Geon-ha Kim
principal investigator · Ewha Womans University Mokdong Hospital
Seong-hye Choi
principal investigator · Inha University Hospital
Kee-hyung Park
principal investigator · Gachon University Gil Medical Center

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion